Effectiveness of Galcanezumab and Traditional Oral Migraine Preventive Medications: Interim 3-Month Japan Subgroup Findings from the TRIUMPH Study
Takao Takeshima(Tominaga hospital), Hideaki Katagiri(Eli Lilly (Japan)), Kaname Ueda(Eli Lilly (Japan)), Tsubasa Takizawa(Keio University), Yasuhiko Matsumori(Sendai Medical Center), Zhihong Cai(Eli Lilly (Japan)), Chie Hashimoto(Eli Lilly (Japan)), Daisuke Danno(Tominaga hospital)
Cited by 0
Related Papers
Hallmarks of primary headache: part 1 – migraine
|The Journal of Headache and Pain|2024|174
Spreading depolarizations trigger caveolin‐1–dependent endothelial transcytosis
|Annals of Neurology|2018|107
International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine
|Cephalalgia|2024|107
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
|Cephalalgia|2024|106
Spreading depression as a preclinical model of migraine
|The Journal of Headache and Pain|2019|104